Jasper Therapeutics, Inc. (JSPR)

20.40 -0.78 (-3.68%) At close: 04:00PM EDT

Jasper Therapeutics, Inc.

2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400
https://www.jaspertherapeutics.com/

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 45

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ronald A. Martell	President, CEO & Director	892.45k	N/A	1962
Mr. Herbert C. Cross	CFO & Corporate Secretary	N/A	N/A	1972
Dr. Luca Di Noto Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A
Mr. David Ku M.D.	Vice President of Corporate Development, Portfolio Strategy & Management	N/A	N/A	N/A
Mr. Matthew Ford	Vice President of Human Resources	N/A	N/A	N/A
Dr. Wendy Pang M.D., Ph.D.	Senior Vice President of Research & Translational Medicine	N/A	N/A	N/A
Dr. Edwin Jonathan Tucker M.D.	Chief Medical Officer	N/A	N/A	1972
Ms. Patricia Carlos	Senior Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Corporate governance

Jasper Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.